CONNECT WITH US
HealthTech

HealthTech

#CTAD26: Biogen’s tau drug slows Alzheimer’s more after nearly two years

Endpoints News logo

Published on

Add as a preferred source on Google
#CTAD26: Biogen’s tau drug slows Alzheimer’s more after nearly two years

Bio­gen says low dose of its ex­per­i­men­tal tau-re­duc­ing drug fares even bet­ter af­ter near­ly 2 years

BOSTON — The ben­e­fits of Bio­gen’s ex­per­i­men­tal Alzheimer’s drug seem to get bet­ter with time. Over the sum­mer, Bio­gen re­port­ed that the low­est dose of its …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.